We're presenting data from our Phase 1 dose-escalation clinical study of BDC-3042 at the?American Association for Cancer Research?annual meeting! Read our press release for more details on our poster presentations: https://bit.ly/4c1FWa2. #AACR25 #immunooncology #colorectalcancer #lungcancer #pancreaticcancer
Bolt Biotherapeutics, Inc.
生物技术
REDWOOD CITY，California 9,129 ä½å…³æ³¨è€…
关于我们
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody? Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
- 网站
-
https://boltbio.com/
Bolt Biotherapeutics, Inc. 的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- REDWOOD CITY，California
- 类型
- 上市公å¸
- 创立
- 2015
地点
-
主è¦
获å–路线
900 CHESAPEAKE DRIVE
US，California，REDWOOD CITY，94063
Bolt Biotherapeutics, Inc. 员工
动æ€
-
Today #BoltBio reported financial results for the fourth quarter & full year 2024 and provided corporate updates. Learn more: https://bit.ly/4j0aMCs
-
-
According to the?American Cancer Society, #ColorectalCancer is the third most common cancer worldwide. Join us in recognizing Colorectal Cancer Awareness Month as we shine a light on this disease that will affect about 1 in 24 people in their lifetimes. At Bolt, we’re developing our dectin-2 targeting antibody, BDC-3042, for the potential treatment of CRC. Learn more about our work:?https://www.boltbio.com/
-
-
In recognition of #EmployeeAppreciationDay, we’d like to thank each member of #TeamBolt for their tireless efforts in furthering our mission of finding better ways to treat cancer. We appreciate all that you do!
-
-
In recognizing International Day of Women and Girls in Science this week, we're highlighting our VP of Portfolio and Program Management, Pam Howland. Pam shared with us her mentors, interest in science, and advice for girls pursuing #STEM fields. Read her responses below. #IDWGS #WomenInSTEM #WomenInScience #RepresentationMatters #TeamBolt
-
-
Today, with our collaborators at Toray Industries, Inc., we announced that the target of our worldwide co-development collaboration is Caprin-1, a novel cancer target discovered by Toray. This co-developed Boltbody? #ISAC will be applicable to multiple solid tumor types. Learn more about the?target and our collaboration:?https://bit.ly/40MBK92
-
-
From our #TeamBolt family to yours,?we’re wishing you a happy, healthy, and safe holiday season! Thank you for following our story as we progress our mission to leverage the immune system for a better way to treat cancer. Here's to an exciting 2025!
-